Compare Biogen Inc (BIIB) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs General Dynamics Corporation — how do they compare? Biogen Inc trades at $208.84 (market cap $30.13B), while General Dynamics Corporation trades at $394.69 (market cap $106.03B). The key difference: General Dynamics Corporation is far larger — about 3.5× Biogen Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GD | |
|---|---|---|
Market Cap | $30.13B | $106.03B |
Sector | Health | Industrials |
52-Week High | $216.63 | $395.97 |
52-Week Low | $128.93 | $312.53 |
Enterprise Value | $37.20B | $111.17B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
General Dynamics (GD) trades at $392.68, down 0.83% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $4.24 versus $3.96 expected. The stock shows bullish technical signals with moving averages supporting upward momentum, while fundamentals reveal robust revenue growth to $52.55 billion in 2025 and improving profit margins. Recent contract wins including a $29.5 billion submarine award and a $1.3 billion cybersecurity contract highlight ongoing defense sector strength.
The outlook remains positive with analyst consensus pointing to 8.7% upside to the $427.40 price target, though valuation multiples appear elevated. Key risks include defense budget uncertainties and competitive pressures, while institutional sentiment remains bullish with 57% buy ratings. The company's strong backlog of $136.5 billion provides visibility for future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
